Last reviewed · How we verify
GC203 TIL
At a glance
| Generic name | GC203 TIL |
|---|---|
| Sponsor | Shanghai Juncell Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of TIL in Advanced Solid Tumors (CZ) (PHASE1)
- A Study of GC203 TIL in PDCA (RJ) (EARLY_PHASE1)
- A Study of GC203 TIL in Advanced Solid Tumors (NF) (PHASE1)
- A Study of TIL in Advanced Solid Tumors (DFGD) (EARLY_PHASE1)
- A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital) (EARLY_PHASE1)
- A Study of GC203 TIL in Advanced Malignant Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC203 TIL CI brief — competitive landscape report
- GC203 TIL updates RSS · CI watch RSS
- Shanghai Juncell Therapeutics portfolio CI